These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35333872)

  • 1. Assessing the best time interval between doses in a two-dose vaccination regimen to reduce the number of deaths in an ongoing epidemic of SARS-CoV-2.
    Souto Ferreira L; Canton O; da Silva RLP; Poloni S; Sudbrack V; Borges ME; Franco C; Marquitti FMD; de Moraes JC; Veras MASM; Kraenkel RA; Coutinho RM
    PLoS Comput Biol; 2022 Mar; 18(3):e1009978. PubMed ID: 35333872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimized delay of the second COVID-19 vaccine dose reduces ICU admissions.
    Silva PJS; Sagastizábal C; Nonato LG; Struchiner CJ; Pereira T
    Proc Natl Acad Sci U S A; 2021 Aug; 118(35):. PubMed ID: 34408076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between one and two dose SARS-CoV-2 vaccine prioritization for a fixed number of vaccine doses.
    Hill EM; Keeling MJ
    J R Soc Interface; 2021 Sep; 18(182):20210214. PubMed ID: 34465208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying the effect of delaying the second COVID-19 vaccine dose in England: a mathematical modelling study.
    Imai N; Rawson T; Knock ES; Sonabend R; Elmaci Y; Perez-Guzman PN; Whittles LK; Kanapram DT; Gaythorpe KAM; Hinsley W; Djaafara BA; Wang H; Fraser K; FitzJohn RG; Hogan AB; Doohan P; Ghani AC; Ferguson NM; Baguelin M; Cori A
    Lancet Public Health; 2023 Mar; 8(3):e174-e183. PubMed ID: 36774945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of COVID-19 vaccination strategies with a delayed second dose.
    Moghadas SM; Vilches TN; Zhang K; Nourbakhsh S; Sah P; Fitzpatrick MC; Galvani AP
    PLoS Biol; 2021 Apr; 19(4):e3001211. PubMed ID: 33882066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling direct and herd protection effects of vaccination against the SARS-CoV-2 Delta variant in Australia.
    McBryde ES; Meehan MT; Caldwell JM; Adekunle AI; Ogunlade ST; Kuddus MA; Ragonnet R; Jayasundara P; Trauer JM; Cope RC
    Med J Aust; 2021 Nov; 215(9):427-432. PubMed ID: 34477236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling optimal vaccination strategies against COVID-19 in a context of Gamma variant predominance in Brazil.
    Ferreira LS; de Almeida GB; Borges ME; Simon LM; Poloni S; Bagattini ÂM; da Rosa MQM; Diniz Filho JAF; Kuchenbecker RS; Camey SA; Kraenkel RA; Coutinho RM; Toscano CM
    Vaccine; 2022 Nov; 40(46):6616-6624. PubMed ID: 36210250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A flexible age-dependent, spatially-stratified predictive model for the spread of COVID-19, accounting for multiple viral variants and vaccines.
    Schneider KA; Tsoungui Obama HCJ; Adil Mahmoud Yousif N
    PLoS One; 2023; 18(1):e0277505. PubMed ID: 36662784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study.
    Jentsch PC; Anand M; Bauch CT
    Lancet Infect Dis; 2021 Aug; 21(8):1097-1106. PubMed ID: 33811817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should We Delay the Second COVID-19 Vaccine Dose in Order to Optimize Rollout? A Mathematical Perspective.
    Berkane S; Harizi I; Tayebi A; Silverman MS; Stranges S
    Int J Public Health; 2021; 66():1604312. PubMed ID: 35140580
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-pharmaceutical interventions and COVID-19 vaccination strategies in Senegal: a modelling study.
    Diarra M; Kebir A; Talla C; Barry A; Faye J; Louati D; Opatowski L; Diop M; ; White LJ; Loucoubar C; Miled SB
    BMJ Glob Health; 2022 Feb; 7(2):. PubMed ID: 35193893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India.
    Du Z; Wang L; Pandey A; Lim WW; Chinazzi M; Piontti APY; Lau EHY; Wu P; Malani A; Cobey S; Cowling BJ
    Nat Med; 2022 May; 28(5):934-938. PubMed ID: 35210596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing vaccine allocation for COVID-19 vaccines shows the potential role of single-dose vaccination.
    Matrajt L; Eaton J; Leung T; Dimitrov D; Schiffer JT; Swan DA; Janes H
    Nat Commun; 2021 Jun; 12(1):3449. PubMed ID: 34103510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impacts of SARS-CoV-2 vaccine dose separation and targeting on the COVID-19 epidemic in England.
    Keeling MJ; Moore S; Penman BS; Hill EM
    Nat Commun; 2023 Feb; 14(1):740. PubMed ID: 36765050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of vaccine action and availability and epidemic severity for delaying the second vaccine dose.
    Berec L; Levínský R; Weiner J; Šmíd M; Neruda R; Vidnerová P; Suchopárová G
    Sci Rep; 2022 May; 12(1):7638. PubMed ID: 35538118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis.
    Hogan AB; Winskill P; Watson OJ; Walker PGT; Whittaker C; Baguelin M; Brazeau NF; Charles GD; Gaythorpe KAM; Hamlet A; Knock E; Laydon DJ; Lees JA; Løchen A; Verity R; Whittles LK; Muhib F; Hauck K; Ferguson NM; Ghani AC
    Vaccine; 2021 May; 39(22):2995-3006. PubMed ID: 33933313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study.
    Romero-Brufau S; Chopra A; Ryu AJ; Gel E; Raskar R; Kremers W; Anderson KS; Subramanian J; Krishnamurthy B; Singh A; Pasupathy K; Dong Y; O'Horo JC; Wilson WR; Mitchell O; Kingsley TC
    BMJ; 2021 May; 373():n1087. PubMed ID: 33980718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Technical guidelines for seasonal influenza vaccination in China (2021-2022)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) , Influenza Vaccination TWG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Oct; 42(10):1722-1749. PubMed ID: 34814607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.